Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.1B
58M shares
52-week range
$25.52 – $40.87
63% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.67%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.0M | $159.7M | $305.4M | $437.9M | $582.0M | $714.7M | $868.5M |
| Cost of revenue | $184.0K | $1.6M | $27.7M | $55.5M | $83.5M | $121.2M | $156.8M | $198.3M |
| Gross profit | −$184.0K | $4.4M | $132.0M | $249.9M | $354.4M | $460.8M | $557.9M | $670.1M |
| Gross margin | — | 73.7% | 82.6% | 81.8% | 80.9% | 79.2% | 78.1% | 77.2% |
| R&D | $12.4M | $69.6M | $19.4M | $30.4M | $70.9M | $76.1M | $145.8M | $189.6M |
| Operating income | −$41.4M | −$145.9M | $17.0M | $87.5M | $120.2M | $192.0M | $190.8M | $208.5M |
| EBITDA | −$41.3M | −$142.7M | $1.5M | $80.5M | $146.9M | $221.5M | $233.4M | $255.0M |
| Net income | −$39.9M | −$152.0M | −$36.9M | $34.6M | $181.5M | $128.9M | $145.5M | $158.7M |
| Net margin | — | -2535.1% | -23.1% | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% |
| EPS (diluted) | -1.42 | -2.94 | -1.10 | 0.58 | 2.97 | 2.13 | 2.51 | 2.71 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.0B | $3.43 | $2.80–$4.08 | 7 |
| 2027 | $1.1B | $4.13 | $3.41–$5.32 | 6 |
| 2028 | $1.3B | $4.80 | $1.57–$6.18 | 10 |
| 2029 | $1.5B | $6.33 | $5.44–$6.84 | 4 |
Forward consensus · source: Financial Modeling Prep
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
www.harmonybiosciences.comNo one on the platform currently holds HRMY.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,077,371 | $30.2M |
| Bridgewater Associatesas of 2026-03-31 | 251,506 | $7.0M |
No one on the platform has traded HRMY yet.
| $2.5B |
| — |
| IMCRImmunocore Holdings plc | $30.54 | -1.11% | $1.6B | — |
| JANXJanux Therapeutics, Inc. | $15.13 | +1.27% | $923M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Trading at 13.4× earnings vs its 16.0× historical median P/E.
Fair value ≈ $41.84 · price $35.17 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$XBI is ready to cause a LGNDary RCUS in RYTM n $HRMY n da MAC is back this July ENTA 🐒🍌🧠⏰♾️
View on StockTwits ↗Da chop chop has da huckleberries as It’s all coming together in $HRMY ONTO 🐒🍌🧠⏰♾️
View on StockTwits ↗Chop chop huckleberries as it all comes together in $HRMY ONTO 🐒🍌🧠⏰♾️
View on StockTwits ↗$HRMY 24% already; congrats 🌟🌿🔆 Checkout $IONQ and $NICE
View on StockTwits ↗$HRMY Share Price: $32.44 Contract Selected: Dec 18, 2026 $30 Calls Buy Zone: $4.59 – $5.67 Target Zone: $8.40 – $10.27 Potential Upside: 73% ROI Time to Expiration: 197 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗If Roger starts rocking in $HRMY ???? $XBI gets $LGND ary ONTO 🐒🍌🧠⏰♾️
View on StockTwits ↗Wall St is expecting 1.15 EPS for $HRMY Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/hrmy?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$HRMY Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.56 down -29.11% YoY • Reported revenue of $215.39M up 16.59% YoY
View on StockTwits ↗A lot of biotech names screen cheap right before the story falls apart. $HRMY is interesting because it does not seem to have the usual problems. MagicDiligence currently gives Harmony Biosciences a clean pass based on WAKIX durability, balance sheet strength, and a surprisingly clean risk profile. https://magicdiligence.com/articles/harmony-biosciences-hrmy-a-clean-pass
View on StockTwits ↗market warriors $HRMY $RCUS $ANNA $BNTX $REI flipped red to green HRMY 5.8x vol and RCUS 3.3x show real accumulation, BNTX solid follow-through; REI ANNA lighter suggest mixed short covering
View on StockTwits ↗$HRMY Mizuho analysts stated that they have learned that Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering an amorphous formulation of pitolisant.
View on StockTwits ↗HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? $HRMY $IJR $IWM https://stocktwits.com/news/equity/markets/hrmy-stock-best-intraday-gains-18-months-what-mizuho-analysts-said/cZBIYK9RI69
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.